IFNB1 and myeloid sarcoma: Interestingly, preliminary genome-wide analysis of mRNA expression data from the peripheral blood of patients with MS showed that TIM-3 is significantly induced in responders to IFN-β therapy, whereas non-responders show lower or no TIM-3 induction (22).